Novo Resources Corp. has completed the second tranche of its placement, raising approximately C$1.93 million (A$1.95 million) through the issuance of common shares and options to investors in Canada and overseas. This follows shareholder approval at the recent Annual General Meeting. The funds will support the company's ongoing development efforts, with Northern Star Resources Ltd remaining the largest shareholder at nearly 9.87%. The issued options will be listed on the ASX, providing further capital-raising flexibility through to 2029.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
